News Pfizer files another lawsuit against Metsera, Novo Nordisk Metsera says Novo Nordisk's takeover offer is superior to one filed by Pfizer, and the latter files a new lawsuit to try to force their deal through.
News Pfizer sues to block Novo Nordisk's Metsera takeover bid Pfizer has filed a lawsuit to block a rival, higher bid for obesity therapy developer Metsera from Novo Nordisk, claiming it is anti-competitive.
News Novo tries to push Pfizer aside with $9bn bid for Metsera Novo Nordisk has launched an audacious bid to elope with weight-loss therapy developer Metsera, before it can go ahead with a marriage to Pfizer.
News Can new Tukysa data drop unlock its sales potential? A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.
News Pharma tariffs yet to emerge as Trump seeks more deals Donald Trump looks set to delay the introduction of his tariffs on pharma imports in order to negotiate more deals with drugmakers on drug pricing.
News Trump, Pfizer announce MFN deal; Lilly, others to come At the White House today, President Trump and Pfizer CEO Albert Bourla announced the first of many deals to secure MFN drug prices for US consumers.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.